LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics. LEXEO Expands Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases.
LEXEO Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006. Phase I/II clinical trial in patients with cardiomyopathy associated with Friedreich’s ataxia expected to initiate in 2021 NEW YORK –...
LEXEO Therapeutics Announces Upcoming Data Presentations at the ASGCT 2021 Virtual Annual Meeting In collaboration with Weill Cornell Medicine's Department of Genetic Medicine, LEXEO Therapeutics, a clinical-stage gene therapy company,...
LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 LEXEO TX announces FDA fast track designation granted to LX1001 for the treatment of APOE4 Associated Alzheimer's Disease.
LEXEO Therapeutics Strengthens Management Team with Key Appointments LEXEO strengthens management team with key appointments to accelerate development of clinical-stage pipeline.
Dec 16, 2020Human Gene TherapyPositron emission tomography (PET) images 24 hr after administration of I-124 labeled AAVrh10 by the intracisternal route to a nonhuman...
Dec 2, 2020Slowing Late Infantile Batten Disease Late infantile Batten disease (CLN2 disease) is an autosomal recessive, neurodegenerative lysosomal storage disease caused by mutations...
